HOME >> BIOLOGY >> NEWS
New liver cancer treatment; the current picture

In June, 2000, the Adelaidean reported on promising trials of a new technique to treat patients suffering from cancers of the liver. The researchers have now presented the preliminary results of those trials to the Annual Scientific Meeting of the Royal Australasian College of Surgeons (South Australia).

The surgical team, led by Professor Guy Maddern from Adelaide University's Department of Surgery, developed the technique of inserting electrodes into the tumours and surrounding liver tissue, and then passing small electric currents through them.

This process, termed electrolysis, destroys tumour and liver tissue in much the same way as electrolysis destroys the follicles of unwanted hair. It affects much less normal liver tissue than surgery of a more conventional kind, in which tumours are cut from the liver.

The ten patients treated so far in the ongoing trial at the Queen Elizabeth Hospital had all been evaluated as unsuitable for conventional surgical treatment due to the extent of their tumours. Nine were patients whose colonic cancers had spread to the liver, while one was treated for cancer of the liver itself.

The average follow-up time for the patients was 9 months; the shortest time being 6 months and the longest 43 months. 8 of the 10 patients showed no evidence of residual tumour at the treatment site. 5 of these 8 patients had developed new areas of tumour spread, but 3 showed no evidence of tumour recurrence.

There has been considerable worldwide interest in the trials following the initial release of the story. The Department is continuing to treat new patients using the technique, but Dr Benjamin Teague, Research Registrar in the Department of Surgery, cautions that patients must meet a number of criteria to be considered for treatment.

"They must be fit for major surgery," said Dr Teague," which means having no significant medical conditions that would make them unsuitable for a general anaesthetic
'"/>

Contact: Prof Guy Maddern
guy.maddern@adelaide.edu.au
618-8222-6000
Adelaide University
8-Nov-2001


Page: 1 2

Related biology news :

1. Gene expression in liver tumors and patient prognosis
2. The birth of reproductive health: A difficult delivery
3. Genetic discovery could dramatically reduce need for liver transplants in children
4. Macrophages, not stem cells, correct liver disease by fusion
5. Vacuum assisted deliveries are safe alternative to forceps
6. Nerac delivers journal tracking solution through TOC Journal Watch
7. Beware cancer, insomnia and liver disease UH students are taking aim
8. RNAi delivery system crosses blood-brain barrier to target brain cancer
9. Study may improve survival of transplanted livers
10. Mouse study yields clue to why liver is less prone to rejection, say Pitt researchers
11. Expression of Rb2/p130 and VEGF could serve as potential liver cancer prognosticators

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/22/2019)... ... 21, 2019 , ... The inventors of a new and ... major step forward with that therapy, known as SurVaxM. MimiVax LLC principals Robert ... from Roswell Park in 2012, has entered into a China-exclusive licensing agreement for ...
(Date:11/19/2019)... ... November 19, 2019 , ... Project Lifeline – ... Stores (NACDS) Foundation to address substance use disorder (SUD) – will take ... who have led to the program’s effectiveness in preventing and treating opioid abuse in ...
(Date:11/19/2019)... ... , ... The inaugural Cell & Gene Therapy Day takes place February 27, ... will be chaired by Dr Aiman Shalabi, VP R&D, Cell and Gene Therapies for ... witnessing significant innovation in cell and gene therapies, and we are at a turning ...
Breaking Biology News(10 mins):
(Date:11/6/2019)... ... November 06, 2019 , ... LeadingBiotech ,?an exclusive ... announces its East/West CEO conference to be held January 11-12, 2020 ... Kicking off the week of the J.P. Morgan Healthcare Conference and other biotech ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... it has received CE Mark for its Fusion Bx 2.0 prostate fusion biopsy ... user-friendly interface, the Fusion Bx 2.0 will give urologists across Europe the ability ...
(Date:11/2/2019)... TORONTO (PRWEB) , ... October 31, 2019 , ... ... are not always used to communicating with each other: study managers, principal investigators, ... cause misunderstandings if a party is not informed of the latest data, potentially ...
(Date:11/2/2019)... ... October 31, 2019 , ... ... pharma artificial intelligence pioneer tellic. drug360 brings tellic’s expertise in biomedical language ... allows researchers to quickly uncover relationships between genes, diseases, variants, phenotypes, and other ...
Breaking Biology Technology:
Cached News: